Understanding how Niemann–Pick disease type C–associated lysosomal dysfunction contributes to tau alterations could unveil novel therapeutic avenues, potentially applicable to Alzheimer’s disease.30,31. The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.